Pharmaceutical Executive
Washington DC-As part of its continuing investigation into competition and intellectual property rights, the US Federal Trade Commission and the Antitrust Division of the Department of Justice recently kicked off a series of hearings.
Washington DC-As part of its continuing investigation into competition and intellectual property rights, the US Federal Trade Commission and the Antitrust Division of the Department of Justice recently kicked off a series of hearings. Although concerns about innovator-??generic competition are the main focus, the hearings in Washington and on the West Coast aim to explore wider issues about whether a proliferation of over-broad patents threatens to limit competition in several high-tech industries.
FTC chairman Timothy Muris set the stage for the hearings in a speech last November, spelling out the key issues:
At the same time, a committee on intellectual property issues sponsored by the National Academies of Science is examining the relationship between patent protection and technological advance. The panel is investigating the broad economic impact of changes in patent law in recent decades and expects to issue its findings and recommendations in September 2002.
Executives from biotech companies will discuss "real-world" experiences with patents and competition at the last FTC??Justice hearing scheduled for March 19??20. Testimony from academics, lawyers, and researchers may push Congress to revisit the Waxman-Hatch Act to see if its patent provisions encourage or limit generic drug competition.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.